 Aptose offered a clinical update with its fourth quarter earnings report that included no new safetytoxicity concerns for luxeptinib, suggesting prior signals were one-offs unrelated to the drug. A complete response in the AML study, at what should be a borderline therapeutic dose level, is encouraging, as is anecdotal reports of other patients seeing blast reductions. 